OncoMatch/Clinical Trials/NCT06956391
Ultralow Dose PET Imaging of 18F-FDG Uptake
Is NCT06956391 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies 18F-FDG for healthy volunteer.
Treatment: 18F-FDG — The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for cancer detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-FDG and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours.
Check if I qualifyEligibility summary
For patients with cancer or healthy volunteer.
This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.
US trial sites
- Nuclear Imaging Institute · Englewood, New Jersey
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify